多柔比星的耐药机制  

Resistant mechanisms of doxorubicin

作　　者：冼志荣 张国君[1] 

机构地区：[1]汕头大学医学院附属肿瘤医院乳腺中心,515041

出　　处：《国际肿瘤学杂志》2013年第12期886-889,共4页Journal of International Oncology

基　　金：国家自然科学基金（31271068）;教育部留学回国人员科研基金（教外司留[2011]508号）;广东省乳腺癌诊治研究重点实验室专项资金（粤科财字[2012]352号）

摘　　要：多柔比星广泛应用于乳腺癌等肿瘤的化疗中，但因耐药使其应用受到一定限制。多柔比星耐药的产生机制可能涉及转运蛋白、凋亡蛋白、DNA修复功能、酶等因素。逆转多柔比星耐药的研究也在持续进行，为临床上克服多柔比星耐药提供了有效方案。但具体机制仍有待进一步阐释，并期待提出更合理的策略以提高疗效。Doxorubicin is widely used in chemotherapy of breast cancer and many other cancers. How- ever, doxorubicin resistance restricts its use to some extent. The mechanisms of doxorubicin resistance may involve transport protein, apoptosis protein, DNA repair function, enzyme and other factors. Researches about reversing doxorubicin resistance are ongoing and provide some effective therapeutic regimens to overcome doxo- rubicin resistance clinically. But the specific mechanism of doxorubicin resistance is yet to be elucidated. It is expected that more reasonable and effective counter-measures will be put forward to improve the theraputical effect of doxorubicin.

关 键 词：抗药性 肿瘤 多柔比星 

分 类 号：R979.1[医药卫生—药品]